Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer
<p dir="ltr">Immune response modulation has allowed for breakthrough progress in the treatment of many solid as well as haematological malignancies. To date, immune check-point inhibitors have been approved as first or second line therapy options in a broadening range of metastatic c...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , |
| منشور في: |
2021
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513516764921856 |
|---|---|
| author | Said Dermime (79420) |
| author2 | Maysaloun Merhi (4246147) Taha Merghoub (217303) Nabil E. Omar (16555850) |
| author2_role | author author author |
| author_facet | Said Dermime (79420) Maysaloun Merhi (4246147) Taha Merghoub (217303) Nabil E. Omar (16555850) |
| author_role | author |
| dc.creator.none.fl_str_mv | Said Dermime (79420) Maysaloun Merhi (4246147) Taha Merghoub (217303) Nabil E. Omar (16555850) |
| dc.date.none.fl_str_mv | 2021-12-01T15:00:00Z |
| dc.identifier.none.fl_str_mv | 10.3389/978-2-88971-863-4 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/book/Dynamic_Biomarkers_of_Response_to_Anti-Immune_Checkpoint_Inhibitors_in_Cancer/25764279 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Immunology Oncology and carcinogenesis Immune Checkpoint Inhibitor (ICI) Programmed cell death protein 1 (PD1) Stable disease (SD) Durable Clinical Benefit (DCB) PD-L1 Dynamic biomarkers |
| dc.title.none.fl_str_mv | Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer |
| dc.type.none.fl_str_mv | Text Book info:eu-repo/semantics/publishedVersion text book |
| description | <p dir="ltr">Immune response modulation has allowed for breakthrough progress in the treatment of many solid as well as haematological malignancies. To date, immune check-point inhibitors have been approved as first or second line therapy options in a broadening range of metastatic cancer and increasingly explored in the treatment of early stage tumors. The success of checkpoint inhibitors therapies relies on the observation of potentially long lasting responses in a limited subset of patients, ranging from 10% to 40%, depending on the malignancy subtype. However, in the remaining administered patients, these novel treatments provide a more restricted and shorter lasting effect. Efforts have been made to identify predictive factors of response to immune checkpoint inhibitors, with the aim to prescribe them to patients with a high probability of response and avoid to expose non-responder subjects to their potential side effects. Whilst a range of biomarkers have been investigated, their predictive potential remains unsatisfactory and, to date, the only biomarker used in clinical practice is PD-L1, whose expression in tumor tissues is predictive of response to PD-1 immune checkpoint blockade. However, a proportion, albeit small, of patients with absent PD-L1 tumor expression may still respond to PD-1 blockade, making it difficult to restrict prescription of these therapies solely based on this biomarker. Although other biomarkers have been identified, including tumor mutation burden, mismatch repair deficiency status, immune tumor microenvironment, circulating immune cells and host gut microbiota, none of the candidates tested to date has shown sufficient predictive power to enable their application in the clinical practice. Hence, the search for a biomarker of response to checkpoint inhibitors remains an unmet need.<br><br>Editors: Said Dermine, Maysaloun Merhi, Taha Merghoub.</p><h2>Other Information</h2><p dir="ltr">Published in: Frontiers Research Topics (Frontiers in Immunology and Frontiers in Oncology)<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See book on publisher's website: <a href="https://dx.doi.org/10.3389/978-2-88971-863-4" rel="noreferrer" target="_blank">https://dx.doi.org/10.3389/978-2-88971-863-4</a><a href="https://dx.doi.org/10.3389/978-2-88971-863-4" rel="noreferrer" target="_blank"><br></a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_65e34a31d6d8d190c75ff9d0e810d27c |
| identifier_str_mv | 10.3389/978-2-88971-863-4 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/25764279 |
| publishDate | 2021 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in CancerSaid Dermime (79420)Maysaloun Merhi (4246147)Taha Merghoub (217303)Nabil E. Omar (16555850)Biomedical and clinical sciencesImmunologyOncology and carcinogenesisImmune Checkpoint Inhibitor (ICI)Programmed cell death protein 1 (PD1)Stable disease (SD)Durable Clinical Benefit (DCB)PD-L1Dynamic biomarkers<p dir="ltr">Immune response modulation has allowed for breakthrough progress in the treatment of many solid as well as haematological malignancies. To date, immune check-point inhibitors have been approved as first or second line therapy options in a broadening range of metastatic cancer and increasingly explored in the treatment of early stage tumors. The success of checkpoint inhibitors therapies relies on the observation of potentially long lasting responses in a limited subset of patients, ranging from 10% to 40%, depending on the malignancy subtype. However, in the remaining administered patients, these novel treatments provide a more restricted and shorter lasting effect. Efforts have been made to identify predictive factors of response to immune checkpoint inhibitors, with the aim to prescribe them to patients with a high probability of response and avoid to expose non-responder subjects to their potential side effects. Whilst a range of biomarkers have been investigated, their predictive potential remains unsatisfactory and, to date, the only biomarker used in clinical practice is PD-L1, whose expression in tumor tissues is predictive of response to PD-1 immune checkpoint blockade. However, a proportion, albeit small, of patients with absent PD-L1 tumor expression may still respond to PD-1 blockade, making it difficult to restrict prescription of these therapies solely based on this biomarker. Although other biomarkers have been identified, including tumor mutation burden, mismatch repair deficiency status, immune tumor microenvironment, circulating immune cells and host gut microbiota, none of the candidates tested to date has shown sufficient predictive power to enable their application in the clinical practice. Hence, the search for a biomarker of response to checkpoint inhibitors remains an unmet need.<br><br>Editors: Said Dermine, Maysaloun Merhi, Taha Merghoub.</p><h2>Other Information</h2><p dir="ltr">Published in: Frontiers Research Topics (Frontiers in Immunology and Frontiers in Oncology)<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See book on publisher's website: <a href="https://dx.doi.org/10.3389/978-2-88971-863-4" rel="noreferrer" target="_blank">https://dx.doi.org/10.3389/978-2-88971-863-4</a><a href="https://dx.doi.org/10.3389/978-2-88971-863-4" rel="noreferrer" target="_blank"><br></a></p>2021-12-01T15:00:00ZTextBookinfo:eu-repo/semantics/publishedVersiontextbook10.3389/978-2-88971-863-4https://figshare.com/articles/book/Dynamic_Biomarkers_of_Response_to_Anti-Immune_Checkpoint_Inhibitors_in_Cancer/25764279CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/257642792021-12-01T15:00:00Z |
| spellingShingle | Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer Said Dermime (79420) Biomedical and clinical sciences Immunology Oncology and carcinogenesis Immune Checkpoint Inhibitor (ICI) Programmed cell death protein 1 (PD1) Stable disease (SD) Durable Clinical Benefit (DCB) PD-L1 Dynamic biomarkers |
| status_str | publishedVersion |
| title | Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer |
| title_full | Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer |
| title_fullStr | Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer |
| title_full_unstemmed | Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer |
| title_short | Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer |
| title_sort | Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer |
| topic | Biomedical and clinical sciences Immunology Oncology and carcinogenesis Immune Checkpoint Inhibitor (ICI) Programmed cell death protein 1 (PD1) Stable disease (SD) Durable Clinical Benefit (DCB) PD-L1 Dynamic biomarkers |